Related Experiment Videos
Statins and fracture risk. A systematic review
Sengwee Toh1, Sonia Hernández-Díaz
1Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA. swtoh@hsph.harvard.edu
Pharmacoepidemiology and Drug Safety
|February 9, 2007
Summary
Statins may not prevent fractures, despite some observational studies suggesting a reduced risk. Evidence from randomized trials and significant heterogeneity in observational data do not support a protective effect against bone fractures.
Area of Science:
- Pharmacology and Bone Health
- Cardiovascular Disease Management
- Epidemiology of Fractures
Background:
- Statins, widely used for cholesterol management, have been investigated for potential effects beyond cardiovascular benefits.
- Previous research has yielded conflicting results regarding the association between statin use and fracture risk.
- Understanding the true impact of statins on bone health is crucial for patient care and treatment guidelines.
Purpose of the Study:
- To synthesize current scientific evidence on the relationship between statin consumption and the risk of bone fractures.
- To identify and analyze potential reasons for inconsistencies observed across different studies on statin use and fractures.
Main Methods:
- A comprehensive literature search was performed across major databases (MEDLINE, EMBASE, Cochrane) using relevant keywords.
- Keywords included HMG-CoA reductase inhibitor (statin), osteoporosis, and fractures.
- A meta-analysis was conducted to aggregate and analyze the findings from identified studies.
Main Results:
- Overall, statin use was linked to a 23% lower fracture risk (OR = 0.77).
- This association was observed in case-control and cohort studies but not in post hoc analyses of randomized trials.
- Reduced risk was noted for hip, spine, and other fractures, in both women and men; however, significant heterogeneity and potential publication bias were detected.
Conclusions:
- The current body of evidence does not conclusively support statins as fracture-preventing agents.
- Lack of association in randomized trials, heterogeneity in observational data, and potential confounding factors challenge the protective effect.
- Further rigorous investigation is warranted to clarify the role of statins in bone fracture prevention.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:27Fractures: Bone Repair
Treatment for a fracture is based on the type of break, the bone affected, and the patient's age.
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the procedure...
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the procedure...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...